Sangui BioTech:
- Sales of USD 77,152 in fiscal year 2018
- Costs and loss is further reduced

Witten, October, 02, 2018: In the fiscal year 2018 (01/07/2017 to 30/06/2018) Sangui BioTech International, Inc. achieved revenues from royalty income and product sales of USD 77,152. In the same period of the previous year the comparable revenue amounted to USD 67,653. Due to increased revenues of the wound spray Granulox, the resulting royalty income of 2018 increased by 14% compared to previous year. While revenues in the first half of the year were significantly higher than in the same period of the previous year, a slight decline in revenues had to be recorded in the second half of the year.

The cost - cutting - and liability - protection program adopted in 2016 also had an effect in the reporting period: In fiscal year 2018, operating business expenses were reduced by a further USD 96,624 or 25% to USD 285,135. As a result of this, the operating loss of the fiscal year 2018 decreased compared to the prior year by USD 108,754 to USD 208,045. Accordingly, the cash position of the Company during the reporting period improved.

At the beginning of July 2018, Mölnlycke Health Care acquired all of the shares of SastoMed GmbH, to which Sangui BioTech GmbH has licensed worldwide distribution rights for the Granulox wound spray. The company assumes that, following the successful integration of SastoMed GmbH into the Mölnlycke Group, possible revenue declines during integration can be quickly compensated for. For the full financial year 2019, the company is therefore assuming increasing sales of Granulox and corresponding royalties.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.